Loading stock data…
Surgery Partners (SGRY)
$13.96-0.30 (-2.10%)
After Hours$14.25+0.29 (+2.08%)· Last close Sep 8
Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Surgery Partners, Inc. in the Healthcare sector is trading at $13.96 with a market capitalization of $2.0B. Wall Street consensus targets $18.73 (11 analysts), implying a +34.1% move over the next 12 months. The stock is currently 40% below its 52-week high of $23.44, remaining 5.4% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +34.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $810.90M↓ | $885.00M↑ | $821.50M↓ | $826.20M↑ | $776.00M |
| Gross Profit | $160.20M↓ | $212.20M↑ | $195.30M↓ | $195.60M↑ | $161.90M |
| Operating Income | $84.10M↓ | $124.80M↓ | $135.10M↑ | $121.30M↑ | $89.60M |
| Net Income | -$35.90M↓ | -$15.00M↑ | -$22.70M↓ | -$2.50M↑ | -$37.70M |
Peer Comparison
JNJUNHPFE
Fundamentals
Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency su...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.00B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-4.51%
Volume
Today's trading volume
2.05M
Recent News
Surgery Partners Director Teresa DeLuca Buys 11,250 Shares
As the stock price dips lower, this executive purchase shows confidence in the future of Surgery Partners.
3 Cash-Producing Stocks Walking a Fine Line
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Surgery Partners (SGRY) Stock May Be Undervalued After Q2 Earnings Beat
Surgery Partners has seen its share price fall sharply over the past few years, yet the stock currently screens as cheap on broad valuation checks. That contrast between prolonged share price weakness and an apparently attractive valuation setup is what investors now need to weigh. Over the past 5 years, Surgery Partners stock has declined 70.8%, which means long term holders have absorbed a heavy drawdown that may now be influencing sentiment around the valuation. Recent growth in higher...
Surgery Partners (SGRY) Q2 2026 Earnings Call Transcript
Idaho Falls sale signals shift to pure-play surgical focus.
The Top 5 Analyst Questions From Surgery Partners’s Q2 Earnings Call
Surgery Partners’ second quarter results were received positively by the market, with management highlighting that revenue and adjusted EBITDA came in ahead of expectations. CEO Eric Evans credited growth in higher-acuity surgical procedures—particularly in orthopedics, vascular, and spine—as a primary driver, despite overall surgical case volumes remaining flat. Management also pointed to the company’s ongoing focus on recruiting new physicians and maintaining strong relationships with clinical